Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q1 2022 (← Previous) (Next →)

Filing Date: May 10, 2022

Total Value ($000): $100,171 (100.0% shares, 0.0% debt)

Holdings (10)

CRSP CRISPR Therapeutics AG 31.2%

Value ($000) $31,294 Shares 498,558 Est. Cost $40.26 Unrealized +56.0%

— Passage Bio, Inc. 15.3%

Value ($000) $15,375 Shares 4,959,769 Est. Cost $17.48 Unrealized —

— Gritstone Oncology, Inc. 14.6%

Value ($000) $14,672 Shares 3,561,150 Est. Cost $7767.86 Unrealized —

CRNX Crinetics Pharmaceuticals, Inc. 9.0%

Value ($000) $9,007 Shares 410,360 Est. Cost $17.05 Unrealized +18.7%

— Akero Therapeutics, Inc. 8.8%

Value ($000) $8,766 Shares 617,727 Est. Cost $21200.00 Unrealized —

— Minerva Surgical Inc. 7.5%

Value ($000) $7,532 Shares 1,673,700 Est. Cost $5.14 Unrealized —

— Adverum Biotechnologies, Inc. 6.6%

Value ($000) $6,639 Shares 5,068,233 Est. Cost $9646.10 Unrealized —

— Aligos Therapeutics, Inc. 5.0%

Value ($000) $4,989 Shares 2,320,381 Est. Cost $27.65 Unrealized —

— CymaBay Therapeutics, Inc. 1.7%

Value ($000) $1,691 Shares 543,753 Est. Cost $9871.60 Unrealized —

— Clovis Oncology, Inc. 0.2%

Value ($000) $206 Shares 101,855 Est. Cost $56000.00 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
CRSP	CRISPR Therapeutics AG	498,558	$31,294	31.2%	$40.26	+56.0%	Common Shares	H17182108
—	Passage Bio, Inc.	4,959,769	$15,375	15.3%	$17.48	—	Common Stock	702712100
—	Gritstone Oncology, Inc.	3,561,150	$14,672	14.6%	$7767.86	—	Common Stock	39868T105
CRNX	Crinetics Pharmaceuticals, Inc.	410,360	$9,007	9.0%	$17.05	+18.7%	Common Stock	22663K107
—	Akero Therapeutics, Inc.	617,727	$8,766	8.8%	$21200.00	—	Common Stock	00973Y108
—	Minerva Surgical Inc.	1,673,700	$7,532	7.5%	$5.14	—	Common Stock	60343F106
—	Adverum Biotechnologies, Inc.	5,068,233	$6,639	6.6%	$9646.10	—	Common Stock	00773U108
—	Aligos Therapeutics, Inc.	2,320,381	$4,989	5.0%	$27.65	—	Common Stock	01626L105
—	CymaBay Therapeutics, Inc.	543,753	$1,691	1.7%	$9871.60	—	Common Stock	23257D103
—	Clovis Oncology, Inc.	101,855	$206	0.2%	$56000.00	—	Common Stock	189464100